Table 3.
Overall treatments and adverse events in the 52 included patients.
| Study Population (n = 52) | |
|---|---|
| Treatment during pediatric and adult follow-up | |
| Corticosteroids therapy, n (%) | 49 (94.2%) |
| Cumulative dose, in mg, median (Q1–Q3) | 17,900 (9900-35,200) |
| Duration of treatment, in years, median (Q1–Q3) | 5 (1.38-10.3) |
| Intravenous pulse, n (%) | 25 (48.1%) |
| Other immunosuppressive treatment, n (%) | 25 (48.1%) |
| Duration of treatment, in years, median (Q1–Q3) | 3 (1.1-5) |
| Reason for the treatment | |
| Corticosteroid dependence | 11 (21.1%) |
| Resistance to corticosteroid therapy | 9 (17.3%) |
| Biotherapy | 5 (9.6%) |
| Adverse events of treatment, n patients (%) | 18 (35.3%) |
| Obesity (BMI > 30 kg/m2) | 8 (15.4%) |
| Overweight (BMI > 25 kg/m2) | 4 (7.7%) |
| Insulin-dependent diabetes | 2 (3.8%) |
| Arterial hypertension | 1 (1.9%) |
| Dyslipidemia | 1 (1.9%) |
| Chronic glaucoma | 2 (3.8%) |
| Posterior cataract | 3 (5.8%) |
| Depression | 2 (3.8%) |
| Septic shock | 1 (1.9%) |
| Pneumonia | 1 (1.9%) |
| Corticotrope deficiency 1 | 1 (4%) |
| Reversible amenorrhea 2 | 1 (1.9%) |
1 Among the patients with no more corticosteroid therapy. 2 Secondary to glucocorticoid. Q1: first quartile, Q3: third quartile.